Search
for
Sort by
Research 331–360 of 447
- First clinical cases of leishmaniosis in meerkats (Suricata suricatta) housed in wildlife parks in Madrid, Spain
- Celiac Disease: Beyond Diet and Food Awareness
- Case Report: Baricitinib improved alopecia areata in a pediatric patient with atopic dermatitis
- The 46th Annual Meeting of the Irish Endocrine Society Meeting Programme and Abstracts 2022
- Whitaker syndrome: A case report of autoimmune polyendocrine syndrome type 1 with dilated cardiomyopathy
- Stem-cell therapy in dermatology – Challenges and opportunities
- Disease burden, clinical management and unmet treatment need of patients with moderate to severe alopecia areata; consensus statements, insights, and practices from CERTAAE (Central/Eastern EU, Russia, Türkiye AA experts) Delphi panel
- Treatments for alopecia areata: a network meta-analysis
- Dermatoses in Postmenopausal Women in a Tertiary Health Care Center of Bihar: A Prospective Cross-Sectional Study
- Mite Burden and Immunophenotypic Response to <i>Demodex musculi</i> in Swiss Webster, BALB/c, C57BL/6, and NSG Mice
- High-Frequency Ultrasonography in Hair and Nail Disorders—How It May Be Helpful
- Trichosanthes kirilowii Extract Promotes Wound Healing through the Phosphorylation of ERK1/2 in Keratinocytes
- Targeted Delivery of Zinc Pyrithione to Skin Epithelia
- Oral isotretinoin for acne
- Clinical overview of tinea infection in Ramadi, Iraq
- P‐59 Three cases of opportunistic dermatoses associated with internal diseases in cats
- Ethnomedicinal plants used by traditional healers in the management of HIV/AIDS opportunistic diseases in Rundu, Kavango East Region, Namibia
- The impact of human immunodeficiency virus-related diseases on pigmented skin types
- The dermatology consultant: A retrospective analysis of inpatient dermatology
- Analysis of the scalp of women with AIDS subjected to autopsy: epithelial, follicular, and immunologic aspects
- Updated Integrated Safety Analysis of Ritlecitinib Up to ~5 Years in Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
- Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months In Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
- Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
- High-risk male teenager with concurrent gonorrhea and syphilis infection: An alarming call
- Manifestaciones Cutáneas en el Paciente Inmunocomprometido: Una Revisión Narrativa
- Idiopathic CD4+ T-lymphocytopenia
- Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
- Updated Integrated Safety Analysis of Ritlecitinib up to ~5 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials
- The follicular microbiome in hair-follicle-associated inflammatory diseases: A systematic review
- A New Heterozygous Variant of c.1225_1227delTTC (p.Phe409del) in Insulin Receptor Gene Associated with Severe Insulin Resistance and Hyperandrogenemia in an Adolescent Female with Type A Severe Insulin Resistance Syndrome